Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Galaxy Executive: Expect Ethereum ETF Spot to be Approved in July

Galaxy Executive: Expect Ethereum ETF Spot to be Approved in July

Bitget2024/07/03 06:00

According to a BlockBeats report on July 3, as reported by CryptoSlat, Steve Kurz, the head of asset management at Galaxy Digital, stated that the U.S. SEC may approve a spot Ethereum ETF before the end of July.

Kurz said he expects the spot Ethereum ETF to be approved "within weeks rather than days," but it will happen within a month. Galaxy has been working with the U.S. SEC for several months on its application and noted that its upcoming spot Ethereum ETF is similar to its existing spot Bitcoin ETF (BTCO). Galaxy collaborated with investment management company Invesco to create these two funds.

Kurz also expressed optimism about other spot crypto ETFs outside of Ethereum getting approval. Legislation (including laws defining securities) is necessary and this process will continue even if Biden continues as president.

1
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Citadel warns: Tech stock sell-off is just the first warning sign, AI trading offers "almost no room for error"

The sell-off in tech stocks reflects rising doubts about AI profitability, with Citadel stating that there is very little margin for error in AI trading. Grayscale noted that demand is parabolic, and capital expenditure presents a two-sided risk.

智通财经•2026/10/27 03:08

Daiwa raises Tesla's target price to $390

格隆汇•2026/10/27 02:51
Daiwa raises Tesla's target price to $390

U.S. judge rejects injunction, Novo Nordisk (NVO.US) loses first round in blocking Eli Lilly (LLY.US) weight-loss drug advertisements

On Monday, a U.S. judge dismissed Novo Nordisk's request to prohibit Eli Lilly from continuing to run advertisements for weight-loss drugs. The Danish pharmaceutical company argued that the ads were false and misleading, in a market with annual sales worth tens of billions of dollars.

智通财经•2026/10/27 02:32